October 25, 2017 08:36 AM EDT
Financing

Abl­ynx IPO rais­es $200M for its nanobody plat­form ef­fort

John Carroll

Editor & Founder

Bel­gian biotech Abl­ynx has low­ered its share price but up­sized the num­ber of shares on of­fer in its US IPO, rais­ing $200 mil­lion from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times